N-Methyl-4-(4-pivalamidophenylsulfanyl)picolinamide hemihydrate
2011
Crystal Structure of a New Antitumor Compound
publication
Evidence: moderate
Author Information
Author(s): Ye Ting-Hong, Huang Ting-Ting, Shi Yao-Jie, Xiong Ying, Yu Luo-Ting
Primary Institution: West China Hospital, West China Medical School, Sichuan University
Hypothesis
The title compound is expected to exhibit improved anticancer activity compared to its parent molecule.
Conclusion
The study successfully determined the crystal structure of the compound, revealing its potential as a more effective antitumor agent.
Supporting Evidence
- The compound is a derivative of Sorafenib, known for its antitumor properties.
- The crystal structure was determined using X-ray diffraction techniques.
- The study found that the compound has better in vitro anticancer activity against two tumor cell lines.
Takeaway
Scientists studied a new drug that might help fight cancer better than similar drugs. They looked at its structure to understand how it works.
Methodology
The compound was synthesized and its crystal structure was analyzed using X-ray diffraction.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website